Despite the pandemic, smart investors continue to back world beating technology. So it is with Kromek, who yesterday confirmed that it had raised £13m gross at 15p/share from existing and new shareholders. The proceeds being earmarked to further develop the new ground-breaking biothreat/Covid airborne detector (see below), alongside optimising its CZT medical/nuclear imaging & D3S ‘dirty bomb’ commercialisation strategy. Whilst equally bolstering the balance sheet.
02 Mar 2021
Oversubscribed £13m fund raise to drive growth
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Oversubscribed £13m fund raise to drive growth
Kromek Group Plc (KMK:LON) | 7.0 0 0.7% | Mkt Cap: 44.6m
- Published:
02 Mar 2021 -
Author:
Paul Hill -
Pages:
10
Despite the pandemic, smart investors continue to back world beating technology. So it is with Kromek, who yesterday confirmed that it had raised £13m gross at 15p/share from existing and new shareholders. The proceeds being earmarked to further develop the new ground-breaking biothreat/Covid airborne detector (see below), alongside optimising its CZT medical/nuclear imaging & D3S ‘dirty bomb’ commercialisation strategy. Whilst equally bolstering the balance sheet.